Dr. Reddy’s Laboratories Ltd (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd. has announced the UK launch of Versavo (bevacizumab), a biosimilar for several types of cancer treatments, marking the product’s first approval and release in a highly regulated market. Versavo, which has been previously launched in India and other countries, represents the company’s commitment to expanding its biosimilar portfolio globally. The launch underscores Dr. Reddy’s capabilities in developing high-quality biosimilar products and its focus on oncology.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
